Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
A ALIMENTARY TRACT AND METABOLISM
A10 DRUGS USED IN DIABETES
A10B BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
A10BK Sodium-glucose co-transporter 2 (SGLT2) inhibitors
A10BK02 Canagliflozin
D09592 Canagliflozin (USAN/INN) <JP/US>
USP drug classification [BR:br08302]
Blood Glucose Regulators
Antidiabetic Agents
Sodium-Glucose Co-Transporter 2 (SGLT2) Inhbitor
Canagliflozin
D09592 Canagliflozin (USAN/INN)
Cardiovascular Agents
Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitors
Canagliflozin
D09592 Canagliflozin (USAN/INN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
396 Antidiabetic agents
3969 Others
D09592 Canagliflozin (USAN/INN); Canagliflozin hydrate (JAN)
Drug groups [BR:br08330]
Antidiabetic agent
DG02044 Hypoglycemic agent
DG01794 SGLT2 inhibitor
D09592 Canagliflozin
Metabolizing enzyme substrate
DG02924 UGT substrate
DG03188 UGT1A9 substrate
D09592 Canagliflozin
DG03189 UGT2B4 substrate
D09592 Canagliflozin
Transporter substrate
DG01665 ABCB1 substrate
D09592 Canagliflozin
Transporter inhibitor
DG01622 ABCB1 inhibitor
D09592 Canagliflozin
Drug classes [BR:br08332]
Antidiabetic agent
DG01794 SGLT2 inhibitor
D09592 Canagliflozin
DG02044 Hypoglycemic agent
D09592 Canagliflozin
Target-based classification of drugs [BR:br08310]
Transporters
Solute carrier family
SLC5
SLC5A2 (SGLT2)
D09592 Canagliflozin (USAN/INN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D09592
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D09592
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D09592
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D09592
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D09592
Drug transporters
D09592